Document is current
Any future updates will be listed below
-
Authors
Wang, Xuefeng
Li, Tingyi
Slebos, Robbert J. C.
Chaudhary, Ritu
Guevara-Patino, Jose A.
Bonomi, Marcelo
Saba, Nabil F.
Chung, Christine H.
-
Funding
Funding for this research was provided by:
National Institute of Health (R01DE030493)
James and Esther King Biomedical Research Grant (7JK02; 21K04)
- License Information
-
More Information
Article History
Received: 14 December 2024
Accepted: 21 February 2025
First Online: 8 March 2025
Declarations
:
: Conflict of interest: CHC—honoraria from Fulgent, Genmab, AVEO, Seagen, Regeneron, Bicara, Johnson and Johnson, and Exelixis for ad hoc Scientific Advisory Board or steering committee participation. NFS—honoraria from Pfizer, Merck, Aduro, Rakuten, CUE, and Blupoint, Eisai, Astra Zeneca, WebMD, Mirati, Reach MD, Vaccinex, Kura, Biontech, GSK, Aduro, Pfizer for ad hoc Scientific Advisory Board or Data Safety Monitoring Committee and research funding Bristol-Myers Squibb and Exelixis. The other authors do not have conflict of interest to declare.
: As part of a phase I/II study of concurrent cetuximab and nivolumab in patients with R/M HNSCC (NCT03370276), this study was approved by the Scientific Review Committee, the Institutional Review Board at Moffitt Cancer Center and all participate sites.
